首页> 外文期刊>Frontiers in Cardiovascular Medicine >Platelet Microparticles and miRNA Transfer in Cancer Progression: Many Targets, Modes of Action, and Effects Across Cancer Stages
【24h】

Platelet Microparticles and miRNA Transfer in Cancer Progression: Many Targets, Modes of Action, and Effects Across Cancer Stages

机译:癌症进展中的血小板微粒和miRNA转移:许多靶标,作用方式以及跨癌症阶段的影响

获取原文
       

摘要

Platelet-derived microparticles (PMPs) have long been known to increase in circulation in the presence of cancer, and have been considered to be cancer promoting by multiple mechanisms including shrouding of circulating tumor cells allowing immune evasion, inducing a procoagulant state associated with increased risk for venous thromboembolic events in cancer patients, and supporting metastatic dissemination by establishment of niches for anchorage of circulating tumor cells. These modes of PMP-enhanced progression of late stage cancer are generally based on the adhesive and procoagulant surfaces of PMPs. However, it is now clear that PMPs can also act as intercellular signaling vesicles, by fusion with target cells and transfer of a broad array of platelet-derived molecular contents including growth factors, angiogenic modulators, second messengers, lipids, and nucleic acids. It is also now well established that PMPs are major repositories of microRNAs (miRNAs). In recent years, new roles of PMPs in cancer have begun emerging, primarily reflecting their ability to transfer miRNA contents and modulate gene expression in target cells, allowing PMPs to affect cancer development at many stages. PMPs have been shown to interact with and transfer miRNAs to various blood vascular cells including endothelium, macrophages and neutrophils. As each of these contributes to cancer progression, PMP-mediated miRNA transfer can affect immune response, NETosis, tumor angiogenesis, and likely other cancer-associated processes. Recently, PMP miRNA transfer was found to suppress primary tumor growth, via PMP infiltration in solid tumors, anchorage to tumor cells and direct miRNA transfer, resulting in tumor cell gene suppression and inhibition of tumor growth. This mini-review will summarize current knowledge of PMP-miRNA interactions with cancer-associated cells and effects in cancer progression, and will indicate new research directions for understanding platelet-cancer interactions.
机译:长期以来,已知血小板衍生的微粒(PMP)在存在癌症的情况下会增加血液循环,并已被认为是通过多种机制促进癌症的发展,包括遮盖循环的肿瘤细胞以允许免疫逃逸,诱导与风险增加相关的促凝状态用于癌症患者中的静脉血栓栓塞事件,并通过建立壁ches来固定转移的肿瘤细胞来支持转移性传播。这些PMP增强晚期癌症进展的模式通常基于PMP的粘附和促凝表面。然而,现在清楚的是,PMP还可以通过与靶细胞融合并转移大量血小板衍生的分子成分(包括生长因子,血管生成调节剂,第二信使,脂质和核酸)来充当细胞间信号囊泡。现在也已经确定PMP是microRNA(miRNA)的主要存储库。近年来,PMP在癌症中的新作用已经开始出现,主要反映了它们在靶细胞中转移miRNA含量和调节基因表达的能力,从而使PMP在许多阶段影响癌症的发展。 PMP已显示与miRNA相互作用并将其转移至各种血管细胞,包括内皮,巨噬细胞和嗜中性粒细胞。由于这些因素均会导致癌症进展,因此PMP介导的miRNA转移会影响免疫反应,NETNET,肿瘤血管生成以及其他可能与癌症相关的过程。最近,发现PMP miRNA转移可通过实体瘤中的PMP浸润,锚定到肿瘤细胞和直接miRNA转移来抑制原发性肿瘤生长,从而导致肿瘤细胞基因抑制和肿瘤生长抑制。这份小型综述将总结PMP-miRNA与癌症相关细胞相互作用的当前知识以及对癌症进展的影响,并将为了解血小板与癌症相互作用提供新的研究方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号